Europe Vaccines Market to Reach US$ 16,291.0 Mn at CAGR of 5.5% in 2027 | The Insight Partners

Europe Vaccines Market to 2027- Regional Analysis and Forecasts By Technology (Recombinant Vaccines, Conjugate Vaccines, Live Attenuated Vaccines, Inactivated and Subunit Vaccines, and Toxoid Vaccines); Disease Indication (DTP (Diphtheria Tetanus toxoids and Pertussis), Influenza, Hepatitis, Respiratory Syncytial Virus (RSV), and Other Diseases); Route of Administration (Oral, Injectable, and Other Routes of Administration); Patient Type (Pediatric Patients, and Adult Patients), and Country

Publication Month: Jun 2019 | Report Code: TIPRE00005750 | No. of Pages: 154 | Category: Pharmaceuticals | Status: Published

The Europe Vaccines Market is expected to reach US$ 16,291.0 Mn in 2027 from US$ 9,576.2 Mn in 2018. The market is estimated to grow with a CAGR of 5.5% from 2019-2027.

 

The growth of the market is driven by the factors such as increasing awareness programs for vaccination in Europe and increasing vaccines research, and development activities in Europe are likely to grow the vaccines market in the forecast period. Whereas, the vaccines hesitancy in the European region is likely to impact the growth of the vaccines market during the forecast period.

 

Vaccination saves lives and improves quality of life. For instance, Polio is an infectious disease caused by poliovirus and causes muscle weakness that results in an inability to move, which further hampers the quality of life. Polio vaccine protects an individual against polio. The vaccine produces antibodies in the bloodstream against the poliovirus. Due to the strong promotion of Polio vaccine in Europe, the World Health Organization in 2002, declared the European Region polio-free.

The countries in the European region are joining forces to eradicate infectious diseases like measles, diphtheria, rubella, pertussis, and others through vaccinations. There are several vaccination programs, campaigns, conferences, being held in the European region in order to raise awareness among the population. For instance, European Immunization Week (EIW) is renowned across the European Region and is celebrated every April to raise awareness of the importance of vaccination for people’s health and well-being. European Centre for Disease Prevention and Control (ECDC) supports the European Immunization Week campaign undertook by WHO/Europe and provides scientific evidence on vaccination.

 

Furthermore, 38th Euro Global Summit and Expo on Vaccines & Vaccination will be held in June 2020 Frankfurt, Germany. The conference focuses on discussing novel strategies in vaccines and immunology research. The aim of the conference is to encourage quality research and to bring together world-class researchers, international communities, and industrial heads to discuss the new developments and innovations in the fields of vaccines and immunology.

 

The Germany vaccines market is expected to grow at the highest rate during the forecast period due to the driving factors such as growing awareness programs and large funding for development of vaccines. The robust R&D activities in the country are likely to drive the market for vaccination in the country. The growth rate of the market in the region is estimated to be 6.4% during the forecast period. Therefore, considering the above mentioned factors, the growth of the market in the country is likely to contribute the largest share in the Europe region during the forecast period.

EUROPE VACCINES– MARKET SEGMENTATION

By Technology

  • Recombinant vaccines
  • Conjugate Vaccines
  • Live Attenuated Vaccines
  • Inactivated Vaccines
  • Toxoid Vaccines

EUROPE VACCINES – MARKET SEGMENTATION

By Disease Indication

  • DTP (diphtheria, tetanus, and pertussis)
  • Influenza
  • Hepatitis
  • Other Diseases

EUROPE VACCINES – MARKET SEGMENTATION

By Rout of Administration

  • Oral
  • Injectable
  • Other

EUROPE VACCINES – MARKET SEGMENTATION

By Patient Type

  • Adults
  • Pediatric

 

By Country

  • Germany
  • France
  • UK
  • Italy
  • Spain       

 

Companies Mentioned

  • PFIZER INC
  • GlaxoSmithKline plc.
  • Merck & Co., Inc.
  • Sanofi
  • Johnson & Johnson Services, Inc
  • Panacea Biotec Limited
  • Astellas Pharma Inc.
  • NOVAVAX, INC.
  • VBI Vaccines Inc
  • Bavarian Nordic

1.              Introduction

1.1       Scope of the Study

1.2       The Insight Partners Research Report Guidance

2.              Europe Vaccines Market – Key Takeaways

3.              Europe Vaccines Market – Market Landscape

3.1       overview

3.2       Market Segmentation

3.2.1       Europe Vaccines Market – By Technology

3.2.2       Europe Market – By Disease Indication

3.2.3       Europe Vaccines Market – By Route of Administration

3.2.4       Europe Vaccines Market – By Patient Type

3.2.5       Europe Vaccines Market – By Country

3.3       PEST Analysis

4.              Europe Vaccines Market - Key Market Dynamics

4.1       Key Market Drivers

4.1.1       Growing Awareness Programs for Vaccination in Europe

4.1.2       Increasing Vaccines Research and Development Activities in Europe.

4.2       Key Market Restraints

4.2.1       Vaccines Hesitancy in the European region.

4.3       Key Market Opportunities

4.3.1       Growing Prevalence of Infectious Diseases

4.4       Future Trends

4.4.1       New Vaccines In Development

4.5       Impact Analysis

5.              Vaccines Market – Europe Analysis

5.1       Europe Vaccines Market Revenue Forecasts and Analysis

5.2       Market Positioning

5.3       Performance of Key Players

5.3.1       Sanofi

6.              Europe Vaccines Market Analysis – By Technology

6.1       Overview

6.2       Europe Vaccines Market, By Type, 2018 & 2027 (%)

6.3       Europe Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)

6.4       Europe Recombinant Vaccines Market

6.4.1       Overview

6.4.2       Europe Recombinant Vaccines Market Revenue and Forecast to 2027 (US$ Mn)

6.5       Europe Conjugate Vaccines Market

6.5.1       Overview

6.5.2       Europe Conjugate Vaccines Market Revenue and Forecast to 2027 (US$ Mn)

6.6       Europe Live Attenuated Vaccines Market

6.6.1       Overview

6.6.2       Europe Live Attenuated Vaccines Market Revenue and Forecast to 2027 (US$ Mn)

6.7       Europe Inactivated Vaccines Market

6.7.1       Overview

6.7.2       Europe Inactivated Vaccines Market Revenue and Forecast to 2027 (US$ Mn)

6.8       Europe Toxoid Vaccines Market

6.8.1       Overview

6.8.2       Europe Toxoid Vaccines Market Revenue and Forecast to 2027 (US$ Mn)

7.              Europe Vaccines Market Analysis – By Disease Indication

7.1       Overview

7.2       Europe Vaccines Market, By Disease Indication, 2018 & 2027 (%)

7.3       Europe Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)

7.4       Europe DTP (Diphtheria, Tetanus, And Pertussis) Market

7.4.1       Overview

7.4.2       Europe DTP (Diphtheria, Tetanus, And Pertussis) Market Revenue and Forecast to 2027 (US$ Mn)

7.5       Europe Influenza Market

7.5.1       Overview

7.5.2       Europe Influenza Market Revenue and Forecast to 2027 (US$ Mn)

7.6       Europe Hepatitis Market

7.6.1       Overview

7.6.2       Europe Hepatitis Market Revenue and Forecast to 2027 (US$ Mn)

7.7       Europe Other Diseases Market

7.7.1       Overview

7.7.2       Europe Other Diseases Market Revenue and Forecast to 2027 (US$ Mn)

8.              Europe Vaccines Market Analysis – By Route of Administration

8.1       Overview

8.2       Europe Vaccines Market, By Route of Administration, 2018 & 2027 (%)

8.3       Europe Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)

8.4       Europe Oral Market

8.4.1       Overview

8.4.2       Europe Oral Market Revenue and Forecast to 2027 (US$ Mn)

8.5       Europe Injectable Market

8.5.1       Overview

8.5.2       Europe Injectable Market Revenue and Forecast to 2027 (US$ Mn)

8.6       Europe Other Routes of Administration Market

8.6.1       Overview

8.6.2       Europe Other Routes of Administration Market Revenue and Forecast to 2027 (US$ Mn)

9.              Europe Vaccines Market Analysis – By Patient Type

9.1       Overview

9.2       Europe Vaccines Market, By Patient Type, 2018 & 2027 (%)

9.3       Europe Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)

9.4       Europe Pediatric Market

9.4.1       Overview

9.4.2       Europe Pediatric Market Revenue and Forecast to 2027 (US$ Mn)

9.5       Europe Adults Market

9.5.1       Overview

9.5.2       Europe Adults Market Revenue and Forecast to 2027 (US$ Mn)

10.           Europe Vaccines Market Revenue And Forecasts To 2027

10.1.1     Europe Vaccines Market Revenue Overview, by Country (2017) (US$ Mn)

10.1.2     Europe Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

10.1.3     Europe Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)

10.1.4     Europe Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)

10.1.5     Europe Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)

10.1.6     Europe Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)

10.1.7     Europe Vaccines Market Revenue and Forecasts to 2027, By Country (%)

10.1.8     Germany Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

10.1.9     Germany Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

10.1.9.1  Germany Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)

10.1.9.2  Germany Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)

10.1.9.3  Germany Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)

10.1.9.4  Germany Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)

10.1.10  UK Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

10.1.11  UK Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

10.1.11.1 UK Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)

10.1.11.2 UK Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)

10.1.11.3 UK Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)

10.1.11.4 UK Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)

10.1.12  France Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

10.1.13  France Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

10.1.13.1 France Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)

10.1.13.2 France Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)

10.1.13.3 France Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)

10.1.13.4 France Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)

10.1.14  Italy Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

10.1.15  Italy Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

10.1.15.1 Italy Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)

10.1.15.2 Italy Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)

10.1.15.3 Italy Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)

10.1.15.4 Italy Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)

10.1.16  Spain Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

10.1.17  Spain Vaccines Market Revenue and Forecasts to 2027 (US$ Mn)

10.1.17.1 Spain Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)

10.1.17.2 Spain Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)

10.1.17.3 Spain Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)

10.1.17.4 Spain Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)

11.           Vaccines Market –Industry Landscape

11.1     Overview

11.2     Comparative Company Analysis

11.3     Growth Strategies Done by the Companies in the Market, (%)

11.4     Organic Developments

11.4.1     Overview

11.5     Inorganic Developments

11.5.1     Overview

12.           Vaccines Market–Key Company Profiles

12.1     Pfizer Inc.

12.1.1     Key Facts

12.1.2     Business Description

12.1.3     Financial Overview

12.1.4     Product Portfolio

12.1.5     SWOT Analysis

12.1.6     Key Developments

12.2     GlaxoSmithKline plc.

12.2.1     Key Facts

12.2.2     Business Description

12.2.3     Financial Overview

12.2.4     Product Portfolio

12.2.5     SWOT Analysis

12.2.6     Key Developments

12.3     Merck & Co., Inc.

12.3.1     Key Facts

12.3.2     Business Description

12.3.3     Financial Overview

12.3.4     Product Portfolio

12.3.5     SWOT Analysis

12.3.6     Key Developments

12.4     Sanofi

12.4.1     Key Facts

12.4.2     Business Description

12.4.3     Financial Information

12.4.4     Product Portfolio

12.4.5     SWOT Analysis

12.4.6     Key Developments

12.5     Johnson & Johnson Services, Inc.

12.5.1     Key Facts

12.5.2     Business Description

12.5.3     Financial Overview

12.5.4     Product Portfolio

12.5.5     SWOT Analysis

12.5.6     Key Developments

12.6     Panacea Biotec Limited

12.6.1     Key Facts

12.6.2     Business Description

12.6.3     Financial Information

12.6.4     Product Portfolio

12.6.5     SWOT Analysis

12.6.6     Key Developments

12.7     Astellas Pharma Inc.

12.7.1     Key Facts

12.7.2     Business Description

12.7.3     Financial Overview

12.7.4     Product Portfolio

12.7.5     Swot Analysis

12.7.6     Key Developments

12.8     NOVAVAX, INC.

12.8.1     Key Facts

12.8.2     Business Description

12.8.3     Financial Information

12.8.4     Product Pipeline

12.8.5     SWOT Analysis

12.8.6     Key Developments

12.9     VBI Vaccines Inc.

12.9.1     Key Facts

12.9.2     Business Description

12.9.3     Financial Information

12.9.4     Product Portfolio

12.9.5     SWOT Analysis

12.9.6     Key Developments

12.10  BAVARIAN NORDIC

12.10.1  Key Facts

12.10.2  Business Description

12.10.3  Financial Information

12.10.4  Product Pipeline

12.10.5  SWOT Analysis

12.10.6  Key Developments

13.           Appendix

13.1     About The Insight Partners

13.2     Glossary of Terms

13.3     Methodology

13.3.1     Coverage

13.3.2     Secondary Research

13.3.3     Primary Research

 

LIST OF TABLES

Table 1.          Europe Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)

Table 2.          Europe Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)

Table 3.          Europe Vaccines Market Revenue And Forecasts to 2027, By route of administration (US$ Mn)

Table 4.          Europe Vaccines Market Revenue And Forecasts to 2027, By patient type (US$ Mn)

Table 5.          Europe Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)

Table 6.          Europe Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)

Table 7.          Europe Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)

Table 8.          Europe Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)

Table 9.          Germany Vaccines Market Revenue And Forecasts To 2027, By Technology (US$ Mn)

Table 10.        Germany Vaccines Market Revenue And Forecasts To 2027, By Disease Indication (US$ Mn)

Table 11.        Germany Vaccines Market Revenue And Forecasts To 2027, By Route Of Administration (US$ Mn)

Table 12.        Germany Vaccines Market Revenue And Forecasts To 2027, By Patient Type (US$ Mn)

Table 13.        UK Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)

Table 14.        UK Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)

Table 15.        UK Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)

Table 16.        UK Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)

Table 17.        France Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)

Table 18.        France Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)

Table 19.        France Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)

Table 20.        France Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)

Table 21.        Italy Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)

Table 22.        Italy Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)

Table 23.        Italy Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)

Table 24.        Italy Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)

Table 25.        Spain Vaccines Market Revenue And Forecasts to 2027, By Technology (US$ Mn)

Table 26.        Spain Vaccines Market Revenue And Forecasts to 2027, By Disease Indication (US$ Mn)

Table 27.        Spain Vaccines Market Revenue And Forecasts to 2027, By Route of Administration (US$ Mn)

Table 28.        Spain Vaccines Market Revenue And Forecasts to 2027, By Patient Type (US$ Mn)

Table 29.        Organic Developments Done By Companies

Table 30.        Inorganic Developments Done by Companies

Table 31.        Glossary of Terms, Vaccines market

 


The List of Companies

  1. PFIZER INC
  2. GlaxoSmithKline plc.
  3. Merck & Co., Inc.
  4. Sanofi
  5. Johnson & Johnson Services, Inc
  6. Panacea Biotec Limited
  7. Astellas Pharma Inc.
  8. NOVAVAX, INC.
  9. VBI Vaccines Inc
  10. Bavarian Nordic